Cancer vaccine therapy, a therapeutic modality with roots extending back to 1999, presents a promising avenue for improving survival outcomes in patients with KRAS-mutant tumors.[68] Clinical trials have primarily explored 2 categories of vaccines: chimeric antigen receptor dendritic cell vaccines and KRAS peptide vaccines.[69] In a longitudinal analysis of resected pancreatic cancer patients vaccinated with a mutant K-ras construct, the response rate among the 27 patients evaluated was 28%. This evidence concerns the gene KRAS and familial pancreatic carcinoma.